Juergen Wolf. Capmatinib （INC280） in METΔex14-mutated advanced non-small cell lung cancer （NSCLC）: efficacy data from the Phase II GEOMETRY mono-1 study. Abstract #9004. 2019 American Society of Clinical Oncology Annual Meeting （ASCO）, May 31-June 4, 2019, Chicago, IL.
Cappuzzo F, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
Tong JH, et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res 2016;22:3048-56.